ArticleJournal of experimental & clinical cancer research : CR2025
Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) presents a significant therapeutic challenge, as current treatment options provide limited long-term benefits due to issues surrounding their effectiveness and associated adverse effects. Our previous research demonstrated that Proteoglycan-4 (PRG4) enhances the anti-proliferative effect of the multi-kinase inhibitor regorafenib in simple in vitro two-dimensional HCC models. In this study, we aimed to investigate the potential adjuvant role of PRG4 in improving the efficacy of regorafenib within both three-dimensional in vitro and in vivo HCC models.
methodsHuman HCC cells were engineered to stably overexpress PRG4. The effects of PRG4 on cell proliferation, both alone and in combination with regorafenib, were tested in monolayer cultures, Matrigel-embedded spheroids, and an orthotopic xenograft HCC mouse model. Additionally, transcriptomic profiling of spheroids generated from control or PRG4-overexpressing HCC cells, either untreated or treated with regorafenib, was performed.
resultsPRG4 expression partially inhibited HCC tumor growth in vivo and enhanced regorafenib antiproliferative activity, leading to a near-complete tumor regression. This synergistic PRG4 + regorafenib interaction in impairing HCC cell growth was further confirmed in 2D and 3D HCC models in vitro. In addition, PRG4 restrained angiogenesis by hindering endothelial tubulogenesis in vitro. By transcriptomic analysis of matrigel-embedded HCC cell spheroids exposed to PRG4 and/or regorafenib, PDGF pathway emerged as a target of PRG4 + regorafenib, corroborating the role of PRG4 in impairing angiogenesis. The G
conclusionsPRG4 demonstrated antitumor activities in vivo and shows promise as an adjuvant to enhance therapeutic interventions in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.